Key facts
- Specifix’s last known valuation is $2.2M (Dec 2024).
- It has raised $310K; the latest was Seed Round ($140K) in Dec 2024.
- Notable investors include Imec.istart, BlueHealth Innovation Centre, Start It X, University of Antwerp.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Specifix
- ·The full record, as it builds
Funding rounds
No funding rounds for Specifix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Specifix
Developer of an AI-powered application designed to deliver optimal care efficiently. The company uses artificial intelligence and 3D technology to minimize errors in bone fracture treatment and save time in pre-operative planning, enabling orthopedic surgeons to treat patients with precision and reduce errors.
- Sector
- Healthcare
- HQ
- Antwerp, Belgium
- Founded
- 2023
- Employees
- 6
- Website
- specifix.online/
- Ownership
- Privately Held (backing)
Specifix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Specifix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Specifix in its N-PORT filings yet. We sweep new filings monthly.